Orasure Technologies Inc. 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Orasure Technologies, Inc., covering the period ended June 30, 2009. The company develops, manufactures, and markets oral fluid diagnostic products, specimen collection devices, and cryosurgical medical devices. Key products include the OraQuick ADVANCE rapid HIV-1/2 antibody test and Intercept drug testing systems.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Total Revenues | $34,530,012 | $37,035,017 |
| Gross Profit | $20,851,976 | $21,786,273 |
| Gross Margin | 60.4% | 58.8% |
| Net Loss | $(6,777,653) | $(241,557) |
| Loss Per Share (Basic & Diluted) | $(0.15) | $(0.01) |
| Cash and Cash Equivalents | $63,019,261 | $39,565,218 |
| Short-term Investments | $16,143,003 | $42,957,467 |
| Total Liquidity (Cash + Investments) | $79,162,264 | $82,522,685 |
| Long-term Debt | $8,041,679 | $8,301,440 |
| Net Cash Used in Operating Activities | $(1,641,357) | $(1,914,592) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 7% year-over-year. This was driven by a 19% drop in substance abuse testing (due to economic conditions and high unemployment) and a 17% drop in cryosurgical systems (due to lower sales to European distributor SSL). These declines were partially offset by a 2% increase in infectious disease testing, largely due to a switch to a direct sales model for the U.S. hospital market.
- Net Loss Expansion: The net loss widened significantly from $242k to $6.8 million. This increase is primarily attributable to a $3.0 million non-cash impairment charge related to Hepatitis C (HCV) patents and product rights, which management no longer believes will generate future sales in developing markets.
- Manufacturing Disruption: In Q2 2009, the company experienced a manufacturing issue with a component for the OraQuick HIV test, leading to inventory shortages, product allocation, and a 16% revenue drop in the U.S. public health market. This issue was resolved in Q3 2009.
- One-Time Income in Prior Year: The 2008 period included a $4.9 million "Other Income" payment from Schering-Plough to resolve patent litigation, which is not present in the 2009 period.
Guidance, Outlook, and Risks
- Regulatory Updates: The FDA has requested additional clinical testing for the OraQuick HCV test to support claims for venous whole blood and oral fluid. The company is conducting these studies. For the OraQuick HIV OTC test, the FDA indicated that results should be reviewed by the Blood Products Advisory Committee (BPAC) before proceeding with a PMA application.
- Manufacturing Outlook: Management expects to eliminate the backlog of OraQuick HIV orders and return to normal inventory levels over the next several months following the resolution of the Q2 manufacturing issue.
- Economic Risks: The company cites the ongoing economic downturn, high unemployment, and credit market disruptions as factors negatively impacting workplace drug testing sales and potentially delaying customer payments.
- Legal Proceedings: A patent infringement lawsuit filed by Inverness Medical Innovations and Church & Dwight regarding the OraQuick HIV test is ongoing. A Markman hearing is scheduled for October 5, 2009. The company intends to defend vigorously but cannot determine the potential impact.
- Liquidity: The company holds approximately $79.2 million in cash and short-term investments, which management believes is sufficient to fund operations through the end of 2010. A $4 million working capital line of credit expired in June 2009 and was not renewed due to sufficient cash reserves.
Investor Verification Checklist
- Verify the timeline and cost estimates for the additional FDA-mandated clinical trials for the OraQuick HCV test.
- Monitor the resolution of the OraQuick HIV manufacturing backlog and the impact on Q3 and Q4 revenue recognition.
- Track the outcome of the Inverness Medical patent infringement lawsuit and associated legal costs.
- Assess the sustainability of the direct sales model for the U.S. hospital market following the termination of the Abbott Laboratories distribution agreement.
- Review the progress of the new domestic OTC cryosurgical brand ("Freeze 'n Clear Skin Clinic") and its ability to offset declines in international distributor sales.